Core Insights - Cuprina Holdings has appointed Dr. Ronald A. Sherman as Medical and Scientific Director, effective September 2025, enhancing its expertise in medical maggot therapies [1][3] - The company has secured a licensing agreement for the FDA clearance to market Lucilia sericata Medical MaggotsTM, allowing it to manufacture and distribute these maggots for maggot debridement therapy (MDT) in the U.S. [2][4] - Cuprina is updating its FDA submission for another species of medical maggots, Lucilia cuprina, which could lead to holding two FDA clearances for different maggot species in MDT [3][4] Company Overview - Cuprina Holdings is a Singapore-based biomedical and biotechnology company focused on developing products for chronic wound management and the health and beauty sectors [10] - The company aims to utilize materials from natural sources to create innovative wound care products that meet international standards [10] Market Potential - The U.S. market for maggot debridement therapy was valued at $13.9 million in 2024 and is projected to grow at a CAGR of 10.1% to reach $24.8 million by 2030, driven by the increasing prevalence of chronic wounds and demand for minimally invasive treatments [9]
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market